Mylan's Herceptin Advisory Committee May Be First Bumpy One For A Biosimilar
US FDA did not address production problems in its briefing document for upcoming Oncologic Drugs Advisory Committee meeting, but manufacturing deficiencies found at Biocon's facility could prompt questions.
